![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first... Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). Show more
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (βCocrystalβ or the βCompanyβ) today reported favorable safety and tolerability results from the...
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.βs (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A...
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed...
BOTHELL, Wash., May 01, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (βCocrystalβ or the βCompanyβ) announces completion of enrollment of 78 subjects who were infected with...
FDA feedback following the Companyβs submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0504 | 2.24 | 2.25 | 2.4943 | 2.1 | 49631 | 2.25691059 | CS |
4 | -0.0996 | -4.15 | 2.4 | 2.7804 | 2.1 | 28650 | 2.35716028 | CS |
12 | 0.7604 | 49.3766233766 | 1.54 | 3.1 | 1.4885 | 35366 | 2.25486206 | CS |
26 | 0.6904 | 42.8819875776 | 1.61 | 3.1 | 1.325 | 23519 | 2.01379288 | CS |
52 | -0.3396 | -12.8636363636 | 2.64 | 3.285 | 1.325 | 24272 | 2.13034187 | CS |
156 | -11.0196 | -82.7297297297 | 13.32 | 17.88 | 1.325 | 491591 | 11.71918955 | CS |
260 | -23.2488 | -90.9961955756 | 25.5492 | 49.2 | 1.325 | 2053650 | 18.84665332 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions